Omnipaque

PreclinicalSmall molecule

UUniversity of Alabama at Birmingham

Omnipaque is one of 15 small molecule programs targeting Ultrasound. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

UltrasoundUnknown status

UltrasoundPreclinical

Unknown status

Competition

Competitive Landscape

18 competitors in Ultrasound

#DrugCompanyPhaseTrials

Reglan

IIstituto Clinico Humanitas

Phase 3

1 2

Sonovue

BBracco Diagnostics, Inc

Phase 3

2 3

Tegretol

Novartis

Phase 1

1 4

Robitussin

Pfizer

Phase 1

1 5

Sulfur Hexafluoride

TTurku University Hospital

Phase 3

2 6

Nimotop

AAzurity Pharmaceuticals

Phase 1

1 7

Ativan

BBausch Health Americas, Inc.

Phase 1

1 8

Carbocaine

Pfizer

Preclinical

1 9

Marcaine

IInnocoll

Preclinical

4 10

Sulfur Hexafluoride Lipid Microspheres

Jjohn eisenbrey

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vascular Access1 trial

Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac Catheterization

Completed·CCentro Cardiológico del Caribe, Columbia·Phase 3·NCT01984411·220 enrolled

Adhesive Small Bowel Obstruction1 trial

Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol

Withdrawn·TThe Guthrie Clinic·N/A·NCT02928458

Ultrasound1 trial

Ultrasound-guided LMBB by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method

Unknown status·EErasme University Hospital·N/A·NCT05930236·40 enrolled

Coronary Atherosclerosis1 trial

Effect of Evolocumab on Coronary Atherosclerosis

Completed·—·Phase 3·NCT03689946·55 enrolled

Oral1 trial

Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT00478556·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Omnipaque. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omnipaque compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omnipaque. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Alabama at Birmingham

Omnipaque

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vascular Access1 trial

Adhesive Small Bowel Obstruction1 trial

Ultrasound1 trial

Coronary Atherosclerosis1 trial

Oral1 trial

References

Drug Info

Quick Facts

Related News